3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
93
Neoplasm Metastasis
6
Prostatic Neoplasms, Castration-Resistant
3
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Neoplasms
2
Genital Diseases, Male
2
Urogenital Neoplasms
1
Stage II Prostate Adenocarcinoma
1
Small Cell Lung Carcinoma
1
Sleep Initiation and Maintenance Disorders
1
Prostate Cancer With ≤10 Bone Metastases
1
Prostate Cancer Metastatic Disease
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Patient Preference
1
Non-metastatic Prostate Cancer
1
Newly Diagnosed Oligometastatic Prostate Cancer
1
Neoplasms by Site
1
Neoadjuvant Therapy
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
1
Metastatic Castration-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-Resistant Prostate Cancer
1
Metastatic Castrate-sensitive Prostate Cancer
1
Low Risk Prostate Cancer
1
High-Risk and Oligometastatic Prostate Cancer
1
High Risk Prostate Cancer
1
Interventions
pembrolizumab
6
Radiosurgery
5
Docetaxel
5
enzalutamide
4
darolutamide
3
Radiotherapy
3
Everolimus
3
Androgen Antagonists
3
relugolix
2
luprolide acetate gel depot
2
Surveys and Questionnaires
2
Standard of Care
2
Radiotherapy, Image-Guided
2
Radiofrequency Ablation
2
Panobinostat
2
Leuprolide
2
Abiraterone Acetate
2
trastuzumab deruxtecan
1
talazoparib
1
spartalizumab
1
siremadlin
1
sipuleucel-T
1
sargramostim
1
resiquimod
1
polysaccharide-K
1
poly ICLC
1
palbociclib
1
olaparib
1
liposomal doxorubicin
1
ixabepilone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
apalutamide
×
Genitourinary
×
Clear all
NCT06592924
2026-04-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3
Recruiting
830 enrolled